J Biol Chem, Vol. 275, Issue 6, 4177-4182, February 11, 2000

Catalytic Activities of Mitochondrial ATP Synthase in Patients with Mitochondrial DNA T8993G Mutation in the ATPase 6 Gene Encoding Subunit a^*

Alessandra Baracca, Silvia Barogi^§, Valerio Carelli^¶, Giorgio Lenaz, and Giancarlo Solaini^§

From the ^§ Scuola Superiore di Studi Universitari e di Perfezionamento S. Anna, Settore di Medicina, Via Giosuè Carducci 40, 56127 Pisa, Italy, the  Dipartimento di Biochimica, Università di Bologna, 48026 Bologna, Italy, and the ^¶ Department of Ophthalmology, University of Southern California School of Medicine, Los Angeles, California 90033

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

We investigated the biochemical phenotype of the mtDNA T8993G point mutation in the ATPase 6 gene, associated with neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP), in three patients from two unrelated families. All three carried >80% mutant genome in platelets and were manifesting clinically various degrees of the NARP phenotype. Coupled submitochondrial particles prepared from platelets capable of succinate-sustained ATP synthesis were studied using very sensitive and rapid luminometric and fluorescence methods. A sharp decrease (>95%) in the succinate-sustained ATP synthesis rate of the particles was found, but both the ATP hydrolysis rate and ATP-driven proton translocation (when the protons flow from the matrix to the cytosol) were minimally affected. The T8993G mutation changes the highly conserved residue Leu¹⁵⁶ to Arg in the ATPase 6 subunit (subunit a). This subunit, together with subunit c, is thought to cooperatively catalyze proton translocation and rotate, one with respect to the other, during the catalytic cycle of the F₁F₀ complex. Our results suggest that the T8993G mutation induces a structural defect in human F₁F₀-ATPase that causes a severe impairment of ATP synthesis. This is possibly due to a defect in either the vectorial proton transport from the cytosol to the mitochondrial matrix or the coupling of proton flow through F₀ to ATP synthesis in F₁. Whatever mechanism is involved, this leads to impaired ATP synthesis. On the other hand, ATP hydrolysis that involves proton flow from the matrix to the cytosol is essentially unaffected.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Both the neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP)¹ syndrome and the maternally inherited Leigh disease have been associated with the mtDNA T8993G point mutation in the ATPase 6 subunit gene (subunit a) of the mitochondrial ATP synthase (F₁F₀-ATPase), being the variable load of the mutant mtDNA (heteroplasmy) associated with the different clinical expression (1-3).

The ATP synthase is the key enzyme for ATP production in mammalian cells. It catalyzes ADP phosphorylation using a proton electrochemical gradient generated by the electron transport chain (4-7). It is a ubiquitous, evolutionary conserved enzyme composed by two main sectors: F₁, a soluble catalytic sector comprising five different subunits that is bound through two stalks to F₀ (8, 9), and the membrane sector that contains up to 10 different subunits (4, 10). Among these are the evolutionary conserved ATPase 6 and the N,N'-dicycloexylcarbodiimide-binding protein (proteolipid), equivalent to subunits a and c of the Escherichia coli enzyme, respectively (10).

A large body of evidence supports the notion that F-ATPases of all species consist of similar structural motives and that reversible ATP synthesis coupled to a proton flux across F₀ is mediated by conformational changes transmitted from the membrane sector to the catalytic sector of the F₀F₁ complex (4, 11-13). Recent experimental evidence (14-16) supports a mechanical coupling between the F₀ and F₁ sectors based on the rotation of a central rotor, consisting of the smaller subunit(s), with respect to a hexagonal ring made up of the main polypeptides containing the catalytic sites. Energy transduction in this model would occur through a rotation within the F₀ sector powered by proton flow, which promotes ATP synthesis and release. Evidence also suggests that the structural rearrangements concerned with this machinery include subunit c of both bacteria and mitochondria (13, 16). Mutant analyses and chemical modification indicate the existence of intermolecular interactions between the transmembrane helices of subunits c and a. These interactions are thought to be involved in proton translocation since several residues of the E. coli enzyme, including Arg²¹⁰ (equivalent to Arg¹⁵⁹ of the mitochondrial enzyme) and others within the most highly conserved regions of subunits a (residues 190-220) and c (Asp⁶¹, equivalent to Glu⁵⁸ of human subunit c), have been shown to be essential for this function (17-20).

The biochemical effect of the T8993G mutation has not been clarified yet, although it was suggested to be an impairment of the F₁F₀-ATPase complex possibly due to a proton channel defect. However, it remains unclear whether ATP hydrolysis is affected by the mutation. Vazquez-Memije et al. (21) and Tatuch et al. (2) showed that the ATP hydrolysis rate of both skin fibroblast and muscle mitochondria from patients harboring >95% abnormal mtDNA did not change significantly with respect to controls. Tatuch and Robinson (22), using mitochondria isolated from lymphoblastoid cell lines with high percentage mutant mtDNA, subsequently found the rate of ATP synthesis reduced by 33-46%, whereas the ATPase activity was 42% reduced compared with controls. Similar results were reported by others (23). These findings were considered indirect evidence of impaired proton channel function (F₀) in NARP patients. However, Houstek et al. (24) found the rate of mitochondrial ATP production in 99% mutant fibroblasts 2-fold lower than in normal fibroblasts and proposed that the mutation could induce structural instability of the enzyme complex. Finally, Trounce et al. (25) examined the respiration rate of mitochondria isolated from both patient-derived cell lines and cybrids with the T8993G mutation and found both decreased ADP-stimulated respiration rates and ADP/oxygen ratios suggestive of a proton channel and ADP phosphorylation defect in the F₁F₀-ATPase. However, the proton transport activity of the mutated enzyme has never been measured directly.

To address this point and to clarify whether the ATP hydrolysis rate of the Leu¹⁵⁶-to-Arg mutated mitochondrial F₁F₀-ATPase subunit a was impaired, we analyzed the catalysis and proton translocating properties of the enzyme in platelet-derived submitochondrial particles from three patients, belonging to two unrelated families, harboring at least 80% mutant mtDNA. An ATP-driven proton transport activity similar to that of the enzyme from controls was observed. We analyze this finding in relation to the results of ATP synthesis and hydrolysis rates and discuss the implications for the current model of proton translocation through F₀ and its coupling to the conformational changes in F₁ leading to ATP synthesis.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Materials-- ATP, ADP, oligomycin A, valinomycin, Hepes, Tris, trichloroacetic acid, and ACMA were obtained from Sigma. 1243-102 ATP monitoring reagent, a mixture of luciferin and luciferase, was a product of BioOrbit (Turku, Finland).

Samples Investigated-- We investigated three previously reported Italian patients, from two unrelated Italian families, carrying high percentages of the T8993G mutation. Patients 1 and 2 are two sisters previously reported by Puddu et al. (26), and patient 3 belongs to a second unrelated family (proband of family F) reported by Uziel et al. (27). All three patients presented a disease clinically compatible with the original description of NARP syndrome (1). We also investigated 12 controls randomly chosen from the general population. Informed consent was obtained in all cases.

Isolation of Platelet Mitochondria and Submitochondrial Particles Preparation-- Human platelets were isolated and purified from 100 ml of venous blood under standardized conditions as previously reported (28). To isolate mitochondria, platelets were suspended in a hypotonic medium (10 mM Tris-Cl, pH 7.6); 4 min later, the suspension was centrifuged at 1500 × g for 10 min; and finally, the supernatant was centrifuged at 10,000 × g for 20 min to precipitate mitochondria. This procedure was repeated twice. The mitochondria were suspended at 4-8 mg/ml in 0.25 M sucrose and 2 mM EDTA, pH 8. Coupled submitochondrial particles (SMPs) were prepared essentially according to Baracca et al. (28) by exposing mitochondria to sonic oscillation on a Labsonic U Braun sonicator for 20 s at the minimum output. The particles were suspended in 0.25 M sucrose to give a protein concentration of 6-8 mg/ml and immediately assayed for ATP-driven proton-pumping activity and for ATP hydrolysis and synthesis.

mtDNA Analysis-- Total DNA was extracted from a pellet of the same platelets used for the biochemical assays by the standard phenol/chloroform purification method. To detect the T8993G mutation, a convenient 551-bp segment of mtDNA was amplified by PCR using the pair of primers originally described by Holt et al. (1), Forward/8648-8665 and Reverse/9199-9180, according to the Cambridge sequence. The PCR conditions were as follows: one cycle of denaturation for 5 min at 94 °C; 29 cycles each consisting of denaturation for 80 s at 94 °C, annealing for 100 s at 56 °C, and extension for 120 s at 72 °C; and a final cycle of "superextension" for 5 min at 72 °C. This last cycle minimizes the possible formation of heteroduplexes between mutant and wild-type strands. The presence of the mutation was detected by restriction fragment length polymorphism analysis after digestion with the restriction endonuclease AvaI. The T8993G mutation introduces a new AvaI restriction site; consequently, the 551-bp amplified fragment will be cut in two 345- and 206-bp fragments. The digestion products were separated through a 3% NuSieve-containing 0.5% agarose gel and visualized by UV transillumination after ethidium bromide staining. The co-presence of all three fragments of 551, 345, and 206 bp indicated the heteroplasmy (coexistence of wild-type and mutant mtDNA). The mutation proportion was calculated as the ratio of the 345- and 206-bp fragments versus the 551-bp fragment evaluated as intensity of the bands in the gel photographs using the Molecular Analyst PC image analysis software for the Bio-Rad GS-670 densitometer.

Chemiluminescent Methods for Monitoring ATP Hydrolysis and Synthesis-- The ATP synthesis rate was assayed by incubating 20-30 µg of submitochondrial particles in 25 µl of 0.25 M sucrose, 50 mM Hepes, 0.5 mM EDTA, 2 mM MgSO₄, 2 mM KH₂PO₄, and 0.2 mM ADP, pH 7.4. 20 mM succinate was added to start the reaction. Incubation was carried out for 10 min at 30 °C, and 5 µl of 50% trichloroacetic acid was added to stop the reaction. The mixture was centrifuged to remove precipitated protein, and the resulting extract was assayed for ATP by the luciferin/luciferase chemiluminescent method (29). Three assays were carried out for each sample.

ATP hydrolysis was assayed as follows. Submitochondrial particles (10 µg) were incubated for 10 min at 30 °C in 25 µl of buffer containing 0.25 M sucrose, 50 mM Hepes, and 2 mM MgCl₂, pH 8, and 1 mM ATP was added to start the reaction. To stop the reaction, trichloroacetic acid was added, and non-hydrolyzed ATP was determined in a diluted sample of the reaction mixture by the luciferin/luciferase method as described above. Three assays were carried out for each sample.

Proton-pumping Activity-- The proton-pumping activity coupled to the ATP hydrolysis of submitochondrial particles was determined from the quenching of ACMA fluorescence induced upon 0.8 mM ATP addition to the assay medium as described (30). Briefly, the assay medium contained (in a 1-ml final volume) 0.25 M sucrose, 10 mM Tricine, 50 mM KCl, 2.5 mM MgCl₂, pH 8, 1 µg of valinomycin, 0.5 µM ACMA, and 0.1 mg of submitochondrial particles. The reaction, performed under continuous mixing, was started by the addition of ATP. Two assays of each sample were carried out at 25 °C on a Jasco P450 spectrofluorometer with excitation and emission at 412 and 510 nm, respectively.

Other Methods-- Protein concentration was measured using the method of Lowry et al. (31) in the presence of 1% deoxycholate.

Statistics-- All data are presented as mean ± S.E. The significance of differences was evaluated by unpaired t tests and accepted when p  0.05.

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

mtDNA Analysis-- The results of mtDNA analysis are shown in Fig. 1. All three NARP patients presented high percentages of mutant mtDNA, i.e. 80% or more (range 80-93%), compatible with the heteroplasmy ratios previously reported (26, 27). We performed the restriction fragment length polymorphism analysis using the same PCR method commonly used for diagnostic purposes. An underestimation of the mutant mtDNA ratio could be due to heteroduplex formation, but this effect had been minimized by performing a final superextension cycle as previously reported (32). Moreover, standard curves prepared with PCR products obtained by Tatuch et al. (2) with the same primers we used demonstrated a negligible deviation due to heteroduplex artifacts. Because we are not doing a strict correlation between the mutation load and the biochemical results in the single samples, we can affirm that our biochemical observations are related to a percentage, conservatively estimated, of at least 80% of T8993G mutant mtDNA in the same tissue sample investigated, the platelets. We also excluded the presence of the T8993G mutation in the platelet mtDNA of the controls.

View larger version (49K): [in this window] [in a new window]   Fig. 1.   mtDNA analysis of platelets. The AvaI digestion of PCR product shows, in the first three lanes, the presence of three fragments corresponding to the coexistence of wild-type (551 bp) and mutant (345 and 206 bp) mtDNAs in the patients investigated. Densitometric evaluation indicated the following relative percentages of heteroplasmy: P1, 12% wild-type and 88% mutant; P2, 20% wild-type and 80% mutant; P3, 7% wild-type and 93% mutant. The AvaI digestion indicates that the mutation is T8993G. The T8993C mutation occurring at the very same nucleotide position introduces a HpaII restriction site (but not AvaI) that is thus the restriction enzyme discriminating between the two mutations (33). Mutant mtDNA was absent in the control samples.

ATP Synthase and ATPase Activities of Submitochondrial Particles from Platelets of NARP Patients-- To assess the biochemical implications of the T8993G mutation, we measured rates of coupled ATP synthesis, ATP hydrolysis, and ATP-driven H⁺ pumping. Since the available assays for ATP hydrolysis require large amounts of biological material and the amount of submitochondrial particles obtainable from patients' platelets is small, we used an assay procedure, based on the measurement of the luminescence emitted by the hydrolysis of ATP in the presence of luciferin and luciferase, that consumes as little as 10 µg of protein/assay. Owing to this method, which allowed us to assay ATP hydrolysis and ATP synthesis in very small samples of particles, we could also assay the ATP-driven proton-pumping activity of the particles from the same blood sample.

The submitochondrial particle preparations from both normal human and patients' platelets had similar cytochrome c oxidase (typically, it was 30 nmol/min/mg of protein), whereas the 5'-nucleotidase activity, used as a probe for contamination, was below the assay sensitivity (specific activity < 1 nmol/min/mg of protein for each sample). These findings indicate comparable and low contamination of the particles in control and mutant samples.

The succinate-sustained ATP synthase activity present in the submitochondrial particles from platelets of NARP patients is shown in Table I. The particles from all patients exhibited a greatly reduced ATP synthase activity ranging from 0.11 to 0.25 nmol/min/mg of protein with respect to the control mean of 2.93 nmol/min/mg of protein. Although, on the basis of the evaluated heteroplasmy of the patients' mitochondrial samples, nearly 20% of the F₁F₀ complexes are active, the ATP synthesis rate decreased by a factor of nearly 20 (on the mean basis, 5% residual synthesis activity). Our expected result was 20% residual activity or higher if the greater driving force for each individual normal F₁F₀ complex was taken into account, as according to Hatefi (6) and Matsuno-Yagi and Hatefi (34). However, the observed lower than expected ATP synthesis rate might be only apparent, for instance, given that the mutated F₁F₀ complexes could still fully exert the ATP hydrolysis activity. In fact, at variance with the ATP synthesis, the ATPase activity of the mutated particles was very close to that of controls (37.0 ± 4.5 nmol/min/mg of protein), without any statistically significant difference (p > 0.3) (Table I). This observation rules out the possibility that the content of F₁F₀-ATPase might be different in normal and mutated mitochondrial platelets, thus ruling out that a different content of the enzyme could account for the reduction of ATP synthase activity observed in the NARP patients. Finally, it should be mentioned that the oligomycin sensitivity of the different enzyme activities cannot be used as a reliable indicator of the F₁F₀-ATPase activity since it appears that the inhibitor affects the enzyme from controls and patients differently, as has very recently been suggested (35).

View this table: [in this window] [in a new window]   Table I Mitochondrial activities of the F1F0-ATPase from platelets of patients carrying the Leu156 to Arg mutation in subunit   The data are presented as means ± S.E.M.

ATP-dependent Fluorescence Quenching-- F₁F₀-ATPase-mediated proton-pumping activity in submitochondrial particles prepared from NARP patients' platelets was used as an indication of the enzyme proton channel function and of coupling between transport and catalysis. Acidification of inverted membrane vesicles was monitored by fluorescence of ACMA. Adding ATP to the suspension of SMPs, a time-dependent decrease in the fluorescence of the probe was observed until oligomycin was added (Fig. 2). To our surprise, particles derived from the three NARP patients had ATP-driven proton-pumping activity similar to that of controls, and proton transport was completely abolished when oligomycin was added to the particles. This indicates that the fluorescence quenching was in fact due to the ATP-driven proton translocation through the membrane and that the proton transport activity of the mutated enzyme is as sensitive to the inhibitor as the normal type. Although the quenching responses do not correlate linearly with the actual rate of H⁺ pumping, the use of ACMA has been validated by several authors investigating different types of vesicles (30, 36, 37). Here, we supply evidence that by slowing the ATPase activity of control particles by lowering the ATP substrate concentration, both the ACMA fluorescence quenching rate and the steady-state fluorescence quenching extent were reduced (Fig. 3). Moreover, by inhibiting the enzyme with substoichiometric oligomycin, the ACMA quenching response was reduced (Fig. 3D). These observations indicate that ACMA fluorescence quenching measurements are a reliable means to reveal changes in the F₁F₀-ATPase proton transport activity of platelet submitochondrial particles. Therefore, we conclude that the mutated F₁F₀-ATPase is fully competent for ATP-driven proton transport.

View larger version (21K): [in this window] [in a new window]   Fig. 2.   ATP-driven proton translocation of human submitochondrial particles containing normal and mutated F1F0-ATPases. Proton gradient formation is indicated by quenching the fluorescence of ACMA, as described under "Experimental Procedures." A, SMPs preincubated with oligomycin showing fluorescence quenching upon addition of ATP (30); B, a typical trace of the control; C-E, traces of patients 1-3, respectively. 100 µg of SMP protein in each assay was used, and oligomycin was added at 0.2 µmol/mg of protein.

View larger version (10K): [in this window] [in a new window]   Fig. 3.   ATP-driven quenching of ACMA fluorescence by platelet submitochondrial particles. The cuvette contained 0.2 mg of SMP protein in 1 ml of assay medium (0.25 M sucrose, 10 mM Tricine, 50 mM KCl, 2.5 mM MgCl2, pH 8, 1 µg of valinomycin, and 0.5 µM ACMA (100 µg/ml in ethanol)). The reaction was started by the addition of increasing ATP concentrations, and the fluorescence emission was recorded at 510 nm after excitation at 412 nm. A-C, 0.2, 0.4, and 0.8 mM ATP, respectively, were added. D, the particles were preincubated with 0.2 nmol of oligomycin/mg of protein, and ATP was added at 0.8 mM (final concentration), as in C.

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Platelets have been widely used in investigations of mitochondrial diseases and neurodegenerative disorders (38, 39). However, these studies were limited to mtDNA analysis and electron transfer activities, whereas no investigation has been performed on the protonophoric activity of the energy-conserving complexes. The latter is crucial in the pathophysiology of some disorders due to mtDNA mutations, in particular in NARP and maternally inherited Leigh disease phenotypes associated with the T8993G mutation. This mutation is now recognized as the most frequent mtDNA defect associated with Leigh disease (40), although its biochemical effect is still not fully understood.

The results reported in this work indicate that substitution of Leu¹⁵⁶ with Arg of F₁F₀-ATPase subunit a causes a reduction of the ATP synthesis rate in platelet submitochondrial particles, whereas both ATPase and ATP-driven proton translocation through F₀ are not significantly affected. Thus, the ATP hydrolysis rate of the mutated enzyme, which is controversial in the literature (2, 21-23), appears slightly altered, with no statistically significant difference with respect to the control. The differences in data reported might be ascribed to the different biological systems assayed since Tatuch et al. (2) and Vazquez-Memije et al. (21) did not find any difference in ATPase activity between skin fibroblasts of patients (with >95% abnormal mtDNA) and controls, whereas Tatuch et al. (23) found reduced activity in lymphocyte mitochondria with >95% heteroplasmy, and Hartzog and Cain (41) found 50% decreased activity in mutated E. coli membranes. However, it remains to be seen why the mutated enzyme from different cells behaves differently. The enzyme may be differently expressed or regulated in different cells.

The second point addressed in this work concerns proton translocation. Our data clearly indicate that protons can be translocated by the mutated enzyme as efficiently as by the control, at least in the direction from the matrix (F₁-binding site) to the cytosolic side of the membrane. This observation was unexpected on the basis of reports in the literature (2, 22, 23, 41).

The T8993G mutation changes a highly conserved leucine 156 to an arginine in a transmembrane helix of subunit a. Modeling of F₀ subunits a and c, both thought to be involved in the proton channel (Fig. 4), shows that this mutation has the effect of placing a positive charge in the vicinity of Arg¹⁵⁹, a residue generally thought to play an essential role in both H⁺ transport (13, 19, 42, 43) and the induction of the movement of subunits c relative to subunit a via protonation-deprotonation of the couple a Arg¹⁵⁹/c Glu⁵⁸.

View larger version (19K): [in this window] [in a new window]   Fig. 4.   Schematic representation of proposed transmembrane helices of subunits a and c involved in proton translocation, as modified from Fig. 3 of Hatch et al. (42). The amino acid residues discussed under "Discussion" are indicated. The numbers refer to the amino acid positions in the human subunits. The green lines represent the possible proton pathway; the red broken lines indicate the salt bridges referred to under "Discussion." h, helix.

The proposed topography of the transmembrane helices of subunits a (helix 4 (h4) and helix 5(h5)) and c (helix 2 (h2)) and amino acids considered to be involved in proton translocation through F₀, Arg¹⁵⁹ (210 in E. coli), His¹⁶⁸ (Glu²¹⁹ in E. coli), and Glu¹⁹⁴ (His²⁴⁵ in E. coli), are shown in Fig. 4. According to the alternative mechanism proposed by Hatch et al. (42), during ATP synthesis, protons from the intermembrane space, through the involvement of Glu¹⁹⁴ and His¹⁶⁸, would move to Glu⁵⁸ of subunit c. This would destabilize the ionic interaction between that Glu⁵⁸ residue and Arg¹⁵⁹ of subunit a. Arg¹⁵⁹ would then form a salt bridge with the next Glu⁵⁸, with the energy released driving the rotation of the ring of subunits c relative to subunit a (44), and a proton would be released from this residue to the matrix side of the membrane. This mechanism implies that the energy released by the H⁺ moving down its concentration gradient drives the relative motion of the subunits as described above. One could speculate that the presence of Arg instead of Leu in position 156 of subunit a could impede the rotation of subunits c relative to subunit a due to a possible salt bridge between Arg¹⁵⁶ of the mutated enzyme and Glu⁵⁸ of that subunit c next to that interacting with Arg¹⁵⁹, therefore inhibiting the ATP synthase activity of the mutated enzyme. In contradistinction, the driving force for the reverse reaction is ATP hydrolysis on F₁ that moves the asymmetric rotor, of which the ring of subunits c is part (16). ATP-driven rotation of subunits c relative to subunit a might force H⁺ to be released from the couple a Arg¹⁵⁹/c Glu⁵⁸ to the cytosolic side of the membrane, whatever amino acid residue is present in position 156 of subunit a.

The experimental data may also be interpreted in light of another popular model for F₁F₀-ATPase proton transport coupled to subunit rotation (43), whereby the protons flow from the mitochondrial matrix side to the couple a Arg¹⁵⁹/c Glu⁵⁸, where the movement of subunits is induced, and then to the cytoplasm, no matter whether Leu or Arg is in position 156. The opposite flow of protons, from the cytoplasm to the matrix, appears most difficult to visualize in the mutated enzyme; the presence of the positively charged and bulky Arg instead of Leu in the pathway from the cytoplasm to the a Arg¹⁵⁹/c Glu⁵⁸ couple might impede the H⁺ flow, causing a block of subunit rotation and ATP synthesis inhibition.

The results reported in the present paper are consistent with the results of Cain and Simoni (19) in that they found that the mutations of the E. coli residue equivalent to human Leu¹⁵⁶, Leu²⁰⁷ to Cys or Tyr, resulted in partial loss of F₁F₀-ATP synthase activity, but failed to reduce ATP-driven proton-pumping activity. Similarly, in a very recent paper, Jiang and Fillingame (45) reported that changing Leu²⁰⁷ to Cys gave transformant strains that grew considerably slower than the wild type on succinate minimal medium, implying that oxidative phosphorylation was impaired.

Hartzog and Cain (41) reported that ATP synthesis and the ATP-driven proton flux through F₀ were abolished and that ~50% residual ATPase activity was still found in the membrane of an E. coli mutant when subunit a Leu²⁰⁷ was replaced with Arg, in contrast with the present findings, where ATP-driven H⁺ pumping by the mutated mitochondrial enzyme was found to be hardly affected by the mutation. The above data suggest a possible difference between the importance of the homologous residues in E. coli and humans. It has to be considered that the essential residues Glu²¹⁹ and His²⁴⁵ in E. coli are replaced by His¹⁶⁸ and Glu²⁰³, respectively, in humans. Moreover, possible subtle differences between the mammalian and bacterial complexes, for instance, in mechanisms present in the eukaryotic enzyme to control proton translocation through F₀, have to be considered; the mammalian F₁F₀ complex contains seven extra polypeptides located in the membrane domain that play unknown roles (46).

	ACKNOWLEDGEMENTS

We thank Dr. M. Zeviani (Istituto Neurologico "C. Besta," Milano, Italy) and Dr. P. Montagna (University of Bologna) for clinical evaluation of the patients and Dr. G. E. Alexander (National Institutes of Health, Bethesda, MD) and Dr. A. A. Sadun (University of Southern California) for critically reading the manuscript.

	FOOTNOTES

^* This work was supported by Comitato Telethon Fondazione Onlus Project Code 1048.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed. Tel.: 39-050-883320; Fax: 39-050-883215; E-mail: gsolaini@sssup.it.

	ABBREVIATIONS

The abbreviations used are: NARP, neurogenic muscle weakness, ataxia, and retinitis pigmentosa; ACMA, 9-amino-6-chloro-2-methoxyacridine; SMP, submitochondrial particle; bp, base pair(s); PCR, polymerase chain reaction; Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES